Tag: vision loss

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025

Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa

First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026MCO-010 BLA for retinitis pigmentosa is eligible for priority review...

SIFI Announces Reimbursement Approval for AKANTIOR® in Spain

AKANTIOR® is anticipated to become available to Spanish patients on 1st August Spain is the first Country in the world to approve the pricing and...

FHLBank San Francisco Awards $5.1 Million in Grants for Affordable Housing in Nevada

Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential approval

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsVision loss

WSS KICKS OFF BACK-TO-SCHOOL WITH SOCCER STAR HIRVING “CHUCKY” LOZANO AND BASEBALL LEGEND ADRIÁN GONZÁLEZ

SEAN HANNITY TO HOST “WANTED: DEAD OR ALIVE” ON FOX NATION

HIMS & HERS HEALTH, INC. (NYSE: HIMS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Hims & Hers Health, Inc. Investors of Upcoming Deadline

Tag: vision loss

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa

SIFI Announces Reimbursement Approval for AKANTIOR® in Spain

FHLBank San Francisco Awards $5.1 Million in Grants for Affordable Housing in Nevada

Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us